Literature DB >> 10454142

Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease.

M Mogi1, A Togari, T Kondo, Y Mizuno, O Komure, S Kuno, H Ichinose, T Nagatsu.   

Abstract

Using highly sensitive sandwich enzyme-linked immunosorbent assays (ELISA), we measured for the first time the concentrations of brain-derived growth factor (BDNF) in the brain (substantia nigra, caudate nucleus, putamen, cerebellum, and frontal cortex) from control and parkinsonian patients. BDNF in the human brain (the order of ng/mg protein) was significantly lower specifically in the nigrostriatal dopamine (DA) regions from parkinsonian patients than in those from control patients. The concentration of nerve growth factor (NGF) was also significantly decreased in the substantia nigra of parkinsonian patients in comparison with that in the controls. Since BDNF and NGF may play important roles in survival and differentiation of neuronal cells, the present data indicate that the lack of neurotrophins, especially BDNF, may be involved in the pathogenesis of PD during progress of neurodegeneration of the nigrostriatal DA neurons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454142     DOI: 10.1016/s0304-3940(99)00463-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  96 in total

1.  Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.

Authors:  Maryna Baydyuk; Madeline T Nguyen; Baoji Xu
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 2.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

3.  Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells.

Authors:  Elisabeth M Chalovich; Jian-hui Zhu; John Caltagarone; Robert Bowser; Charleen T Chu
Journal:  J Biol Chem       Date:  2006-04-18       Impact factor: 5.157

Review 4.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 5.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 6.  Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease.

Authors:  Anumantha Kanthasamy; Huajun Jin; Suneet Mehrotra; Rajakishore Mishra; Arthi Kanthasamy; Ajay Rana
Journal:  Neurotoxicology       Date:  2009-12-11       Impact factor: 4.294

Review 7.  Parkinson's disease: an update on pathogenesis and treatment.

Authors:  Tom Foltynie; Joshua Kahan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

8.  Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

Authors:  Tobias Gyárfás; Juha Knuuttila; Päivi Lindholm; Tomi Rantamäki; Eero Castrén
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Altered transcription factor trafficking in oxidatively-stressed neuronal cells.

Authors:  Vivek P Patel; Donald B Defranco; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2012-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.